{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:18:07Z","timestamp":1790839087541,"version":"4.1.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006315","name":"ReumaNederland","doi-asserted-by":"publisher","award":["18-2-401"],"award-info":[{"award-number":["18-2-401"]}],"id":[{"id":"10.13039\/501100006315","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Polymyalgia rheumatica (PMR) is an inflammatory rheumatic disease affecting people older than 50, resulting in pain and stiffness of the neck, shoulder, and pelvic girdle. To date, glucocorticoids (GC) remain the cornerstone of treatment, but these have several drawbacks. Firstly, a large proportion of patients do not achieve GC-free remission within either the first (over 70%) or second year of treatment (over 50%). Secondly, GC-related adverse events (AE) occur in up to 65% of patients and can be severe.<\/jats:p>\n                <jats:p>The current EULAR\/ACR guidelines for PMR recommend early introduction of methotrexate (MTX) as a GC sparing agent in patients at risk for worse prognosis. However, earlier trials of low to medium quality only studied MTX dosages of 7.5\u201310\u2009mg\/week with no to modest effect. These doses may be suboptimal as MTX is recommended in higher doses (25\u2009mg\/week) for other inflammatory rheumatic diseases. The exact role, timing, and dose of MTX in PMR remain unclear, and therefore, our objective is to study the efficacy of MTX 25\u2009mg\/week in recently diagnosed PMR patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We set up a double-blind, randomized, placebo-controlled superiority trial (PMR MODE) to assess the efficacy of MTX 25\u2009mg\/week versus placebo in a 1:1 ratio in 100 recently diagnosed PMR patients according to the 2012 EULAR\/ACR criteria. All patients will receive prednisolone 15\u2009mg\/day, tapered to 0\u2009mg over the course of 24\u2009weeks. In case of primary non-response or disease relapse, prednisolone dose will be temporarily increased. Assessments will take place at baseline, 4, 12, 24, 32, and 52\u2009weeks. The primary outcome is the difference in proportion of patients in GC-free remission at week 52.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>No relapsing PMR patients were chosen, since the possible benefits of MTX may not outweigh the risks at low doses and effect modification may occur. Accelerated tapering was chosen in order to more easily identify a GC-sparing effect if one exists. A composite endpoint of GC-free remission was chosen as a clinically relevant endpoint for both patients and rheumatologist and may reduce second order (treatment) effects.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>Dutch Trial Registration, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.trialregister.nl\/trial\/8366\">NL8366<\/jats:ext-link>. Registered on 10 February 2020<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-022-06263-3","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T14:03:19Z","timestamp":1650031399000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Diane E.","family":"Marsman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3911-3515","authenticated-orcid":false,"given":"Thomas E.","family":"Bolhuis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"den Broeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfons A.","family":"den Broeder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aatke","family":"van der Maas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"issue":"10103","key":"6263_CR1","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1016\/S0140-6736(17)31825-1","volume":"390","author":"MA Gonz\u00e1lez-Gay","year":"2017","unstructured":"Gonz\u00e1lez-Gay MA, Matteson EL, Casta\u00f1eda S. Polymyalgia rheumatica. Lancet. 2017;390(10103):1700\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(17)31825-1.","journal-title":"Lancet."},{"issue":"4","key":"6263_CR2","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1136\/annrheumdis-2011-200329","volume":"71","author":"B Dasgupta","year":"2012","unstructured":"Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 Provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012;71(4):484\u201392. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200329.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"6263_CR3","first-page":"65","volume":"32","author":"HM Kremers","year":"2005","unstructured":"Kremers HM, Reinalda MS, Crowson CS, Zinsmeister AR, Hunder GG, Gabriel SE. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol. 2005;32(1):65\u201373.","journal-title":"J Rheumatol"},{"issue":"1","key":"6263_CR4","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1056\/NEJMcp1214825","volume":"371","author":"CM Weyand","year":"2014","unstructured":"Weyand CM, Goronzy JJ. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med. 2014;371(1):50\u20137. https:\/\/doi.org\/10.1056\/NEJMcp1214825.","journal-title":"N Engl J Med"},{"issue":"5","key":"6263_CR5","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/art.22777","volume":"57","author":"A Hutchings","year":"2007","unstructured":"Hutchings A, Hollywood J, Lamping DL, Pease CT, Chakravarty K, Silverman B, et al. Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Care Res. 2007;57(5):803\u20139. https:\/\/doi.org\/10.1002\/art.22777.","journal-title":"Arthritis Care Res"},{"issue":"4","key":"6263_CR6","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1093\/rheumatology\/kep395","volume":"49","author":"SL Mackie","year":"2010","unstructured":"Mackie SL, Hensor EMAA, Haugeberg G, Bhakta B, Pease CT. Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study. Rheumatology (Oxford). 2010;49(4):716\u201322. https:\/\/doi.org\/10.1093\/rheumatology\/kep395.","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"6263_CR7","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1136\/annrheumdis-2015-207492","volume":"74","author":"C Dejaco","year":"2015","unstructured":"Dejaco C, Singh YP, Perel P, Hutchings A, Camellino D, Mackie S, et al. 2015 recommendations for the management of polymyalgia rheumatica: a European League Against Rheumatism\/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2015;74(10):1799\u2013807. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207492.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"6263_CR8","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1136\/annrheumdis-2018-213883","volume":"77","author":"RJ Partington","year":"2018","unstructured":"Partington RJ, Muller S, Helliwell T, Mallen CD, Abdul SA. Incidence, prevalence and treatment burden of polymyalgia rheumatica in the UK over two decades: a population-based study. Ann Rheum Dis. 2018;77(12):1750\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213883.","journal-title":"Ann Rheum Dis"},{"issue":"5 Suppl 68","key":"6263_CR9","first-page":"S143","volume":"29","author":"R Caporali","year":"2011","unstructured":"Caporali R, Cimmino MA, Montecucco C, Cutolo M. Glucocorticoid treatment of polymyalgia rheumatica. Clin Exp Rheumatol. 2011;29(5 Suppl 68):S143\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"6263_CR10","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1007\/s00296-017-3874-3","volume":"38","author":"K Albrecht","year":"2018","unstructured":"Albrecht K, Huscher D, Buttgereit F, Aringer M, Hoese G, Ochs W, et al. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database. Rheumatol Int. 2018;38(4):569\u201377. https:\/\/doi.org\/10.1007\/s00296-017-3874-3.","journal-title":"Rheumatol Int"},{"issue":"3","key":"6263_CR11","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/art.21984","volume":"55","author":"JR Curtis","year":"2006","unstructured":"Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Care Res. 2006;55(3):420\u20136. https:\/\/doi.org\/10.1002\/art.21984.","journal-title":"Arthritis Care Res"},{"issue":"10","key":"6263_CR12","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1002\/art.1780401022","volume":"40","author":"SE Gabriel","year":"1997","unstructured":"Gabriel SE, Sunku J, Salvarani C, O'Fallon WM, Hunder GG. Adverse outcomes of antiinflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum. 1997;40(10):1873\u20138. https:\/\/doi.org\/10.1002\/art.1780401022.","journal-title":"Arthritis Rheum"},{"issue":"12","key":"6263_CR13","doi-asserted-by":"publisher","first-page":"1833","DOI":"10.1136\/ard.2008.100008","volume":"68","author":"JN Hoes","year":"2009","unstructured":"Hoes JN, Jacobs JWG, Verstappen SMM, Bijlsma JWJ, Van der Heijden GJMG. Adverse events of low- to medium-dose oral glucocorticoids in inflammatory diseases: a meta-analysis. Ann Rheum Dis. 2009;68(12):1833\u20138. https:\/\/doi.org\/10.1136\/ard.2008.100008.","journal-title":"Ann Rheum Dis"},{"issue":"22","key":"6263_CR14","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.1001\/jama.2016.5444","volume":"315","author":"F Buttgereit","year":"2016","unstructured":"Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. Polymyalgia rheumatica and giant cell arteritis: a systematic review. JAMA. 2016;315(22):2442\u201358. https:\/\/doi.org\/10.1001\/jama.2016.5444.","journal-title":"JAMA."},{"issue":"9","key":"6263_CR15","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1111\/j.1742-1241.2012.02981.x","volume":"66","author":"T Adizie","year":"2012","unstructured":"Adizie T, Christidis D, Dharmapaliah C, Borg F, Dasgupta B. Efficacy and tolerability of leflunomide in difficult-to-treat polymyalgia rheumatica and giant cell arteritis: a case series. Int J Clin Pract. 2012;66(9):906\u20139. https:\/\/doi.org\/10.1111\/j.1742-1241.2012.02981.x.","journal-title":"Int J Clin Pract"},{"key":"6263_CR16","doi-asserted-by":"publisher","first-page":"120638","DOI":"10.1155\/2013\/120638","volume":"2013","author":"AP Diamantopoulos","year":"2013","unstructured":"Diamantopoulos AP, Hetland H, Myklebust G. Leflunomide as a corticosteroid-sparing agent in giant cell arteritis and polymyalgia rheumatica: a case series. Biomed Res Int. 2013;2013:120638\u20133. https:\/\/doi.org\/10.1155\/2013\/120638.","journal-title":"Biomed Res Int"},{"issue":"8","key":"6263_CR17","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1136\/annrheumdis-2015-208742","volume":"75","author":"V Devauchelle-Pensec","year":"2016","unstructured":"Devauchelle-Pensec V, Berthelot JM, Cornec D, Renaudineau Y, Marhadour T, Jousse-Joulin S, et al. Efficacy of first-line tocilizumab therapy in early polymyalgia rheumatica: a prospective longitudinal study. Ann Rheum Dis. 2016;75(8):1506\u201310. https:\/\/doi.org\/10.1136\/annrheumdis-2015-208742.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"6263_CR18","doi-asserted-by":"publisher","first-page":"2550","DOI":"10.1002\/art.39740","volume":"68","author":"L Lally","year":"2016","unstructured":"Lally L, Forbess L, Hatzis C, Spiera R. Brief report: a prospective open-label phase IIa trial of tocilizumab in the treatment of polymyalgia rheumatica. Arthritis Rheum. 2016;68(10):2550\u20134. https:\/\/doi.org\/10.1002\/art.39740.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"6263_CR19","doi-asserted-by":"publisher","first-page":"e758","DOI":"10.1016\/S2665-9913(21)00245-9","volume":"3","author":"DE Marsman","year":"2021","unstructured":"Marsman DE, den Broeder N, van den Hoogen FHJ, den Broeder AA, van der Maas A. Efficacy of rituximab in patients with polymyalgia rheumatica: a double-blind, randomised, placebo-controlled, proof-of-concept trial. Lancet Rheumatol. 2021;3(11):e758\u2013e66. https:\/\/doi.org\/10.1016\/S2665-9913(21)00245-9.","journal-title":"Lancet Rheumatol"},{"issue":"7","key":"6263_CR20","doi-asserted-by":"publisher","first-page":"493","DOI":"10.7326\/0003-4819-141-7-200410050-00005","volume":"141","author":"R Caporali","year":"2004","unstructured":"Caporali R, Cimmino MA, Ferraccioli G, Gerli R, Klersy C, Salvarani C, et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2004;141(7):493\u2013500. https:\/\/doi.org\/10.7326\/0003-4819-141-7-200410050-00005.","journal-title":"Ann Intern Med"},{"issue":"3","key":"6263_CR21","first-page":"395","volume":"26","author":"MA Cimmino","year":"2008","unstructured":"Cimmino MA, Salvarani C, Macchioni P, Gerli R, Bartoloni Bocci E, Montecucco C, et al. Long-term follow-up of polymyalgia rheumatica patients treated with methotrexate and steroids. Clin Exp Rheumatol. 2008;26(3):395\u2013400.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"6263_CR22","first-page":"624","volume":"23","author":"G Ferraccioli","year":"1996","unstructured":"Ferraccioli G, Salaffi F, De Vita S, Casatta L, Bartoli E. Methotrexate in polymyalgia rheumatica: preliminary results of an open, randomized study. J Rheumatol. 1996;23(4):624\u20138.","journal-title":"J Rheumatol"},{"issue":"6","key":"6263_CR23","first-page":"Cd000957","volume":"2014","author":"MA Lopez-Olivo","year":"2014","unstructured":"Lopez-Olivo MA, Siddhanamatha HR, Shea B, Tugwell P, Wells GA, Suarez-Almazor ME. Methotrexate for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2014;2014(6):Cd000957.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"6263_CR24","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landew\u00e9 R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960\u201377. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210715.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"6263_CR25","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1007\/s00296-012-2580-4","volume":"33","author":"JH Lee","year":"2013","unstructured":"Lee JH, Choi ST, Kim JS, Yoon BY, Kwok S-KK, Kim H-SSH-RH-SR, et al. Clinical characteristics and prognostic factors for relapse in patients with polymyalgia rheumatica (PMR). Rheumatol Int. 2013;33(6):1475\u201380. https:\/\/doi.org\/10.1007\/s00296-012-2580-4.","journal-title":"Rheumatol Int"},{"issue":"4","key":"6263_CR26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1136\/ard.55.4.218","volume":"55","author":"MJ van der Veen","year":"1996","unstructured":"van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsma JW. Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann Rheum Dis. 1996;55(4):218\u201323. https:\/\/doi.org\/10.1136\/ard.55.4.218.","journal-title":"Ann Rheum Dis"},{"key":"6263_CR27","doi-asserted-by":"crossref","unstructured":"Heuvelmans J, den Broeder N, van den Elsen GAH, den Broeder AA, van den Bemt BJF. Effectiveness and tolerability of oral vs subcutaneous methotrexate in patients with rheumatoid arthritis. Rheumatology. 2021:keab313.","DOI":"10.1093\/rheumatology\/keab313"},{"issue":"9","key":"6263_CR28","doi-asserted-by":"publisher","first-page":"e0221823","DOI":"10.1371\/journal.pone.0221823","volume":"14","author":"AM Bujor","year":"2019","unstructured":"Bujor AM, Janjua S, LaValley MP, Duran J, Braun J, Felson DT. Comparison of oral versus parenteral methotrexate in the treatment of rheumatoid arthritis: a meta-analysis. PLoS One. 2019;14(9):e0221823. https:\/\/doi.org\/10.1371\/journal.pone.0221823.","journal-title":"PLoS One"},{"key":"6263_CR29","unstructured":"van Ede AE, Laan RF, Rood MJ, Huizinga TW, van de Laar MA, van Denderen CJ, et al. Effect of folic or folinic acid supplementation on the toxicity and efficacy of methotrexate in rheumatoid arthritis: a forty-eight week, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum. 2001;44(7):1515\u201324. https:\/\/onlinelibrary.wiley.com\/doi\/epdf\/10.1002\/1529-0131%28200107%2944%3A7%3C1515%3A%3AAID-ART273%3E3.0.CO%3B2-7."},{"key":"6263_CR30","unstructured":"Nederlandse Vereniging voor Reumatologie (NVR). CBO Richtlijn Osteoporose en Fractuurpreventie. 2011. https:\/\/www.volksgezondheidenzorg.info\/sites\/default\/files\/cbo_richtlijn_osteoporose-en-fractuurpreventie-2011.pdf. Accessed 13 may 2011"},{"key":"6263_CR31","unstructured":"Nederlandse Vereniging voor Reumatologie (NVR). Richtlijnen. Medicijnen: Methotrexaat 2011. https:\/\/www.nvr.nl\/wp-content\/uploads\/2018\/09\/NVR-Medicijnen-MTX-richtlijn-2009-update-2011.pdf. Accessed 13 may 2019"},{"issue":"2","key":"6263_CR32","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1002\/art.23338","volume":"59","author":"A Binard","year":"2008","unstructured":"Binard A, de Bandt M, Berthelot J-M, Saraux A. Performance of the polymyalgia rheumatica activity score for diagnosing disease flares. Arthritis Rheum. 2008;59(2):263\u20139. https:\/\/doi.org\/10.1002\/art.23338.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"6263_CR33","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1136\/ard.2008.088526","volume":"68","author":"A Binard","year":"2009","unstructured":"Binard A, Lefebvre B, De Bandt M, Berthelot JM, Saraux A. Validity of the polymyalgia rheumatica activity score in primary care practice. Ann Rheum Dis. 2009;68(4):541\u20135. https:\/\/doi.org\/10.1136\/ard.2008.088526.","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"6263_CR34","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1136\/ard.2003.011379","volume":"63","author":"BF Leeb","year":"2004","unstructured":"Leeb BF, Bird HA. A disease activity score for polymyalgia rheumatica. Ann Rheum Dis. 2004;63(10):1279\u201383. https:\/\/doi.org\/10.1136\/ard.2003.011379.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"6263_CR35","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/art.22771","volume":"57","author":"BF Leeb","year":"2007","unstructured":"Leeb BF, Rintelen B, Sautner J, Fassl C, Bird HA. The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission. Arthritis Rheum. 2007;57(5):810\u20135. https:\/\/doi.org\/10.1002\/art.22771.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"6263_CR36","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.3899\/jrheum.161109","volume":"44","author":"SL Mackie","year":"2017","unstructured":"Mackie SL, Twohig H, Neill LM, Harrison E, Shea B, Black RJ, et al. The OMERACT core domain set for outcome measures for clinical trials in polymyalgia rrheumatica. J Rheumatol. 2017;44(10):1515\u201321. https:\/\/doi.org\/10.3899\/jrheum.161109.","journal-title":"J Rheumatol"},{"issue":"3","key":"6263_CR37","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","volume":"76","author":"EM Miloslavsky","year":"2017","unstructured":"Miloslavsky EM, Naden RP, Bijlsma JW, Brogan PA, Brown ES, Brunetta P, et al. Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis. Ann Rheum Dis. 2017;76(3):543\u20136. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210002.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"6263_CR38","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/s41584-020-00550-6","volume":"17","author":"BF Leeb","year":"2021","unstructured":"Leeb BF. What could a new disease activity score for polymyalgia rheumatica do better? Nat Rev Rheumatol. 2021;17(3):185. https:\/\/doi.org\/10.1038\/s41584-020-00550-6.","journal-title":"Nat Rev Rheumatol"},{"key":"6263_CR39","volume-title":"Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg","author":"L Hakkaart-van Roijen","year":"2015","unstructured":"Hakkaart-van Roijen, L, van der Linden, N, Bouwmans, C, Kanters, T, Swan Tan, S. Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. 2015 https:\/\/www.zorginstituutnederland.nl\/binaries\/zinl\/documenten\/publicatie\/2016\/02\/29\/richtlijn-voor-het-uitvoeren-van-economische-evaluaties-in-de-gezondheidszorg\/Richtlijn+voor+het+uitvoeren+van+economische+evaluaties+in+de+gezondheidszorg+%28verdiepingsmodules%29.pdf. Accessed 13 May 2019"},{"issue":"1","key":"6263_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/bmb\/ldq033","volume":"96","author":"SJ Whitehead","year":"2010","unstructured":"Whitehead SJ, Ali S. Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull. 2010;96(1):5\u201321. https:\/\/doi.org\/10.1093\/bmb\/ldq033.","journal-title":"Br Med Bull"},{"issue":"4","key":"6263_CR41","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.jval.2016.01.003","volume":"19","author":"MM Versteegh","year":"2016","unstructured":"Versteegh MM, Vermeulen MK, Evers MAAS, de Wit GA, Prenger R, Stolk AE. Dutch Tariff for the Five-Level Version of EQ-5D. Value Health. 2016;19(4):343\u201352. https:\/\/doi.org\/10.1016\/j.jval.2016.01.003.","journal-title":"Value Health"},{"issue":"4","key":"6263_CR42","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1177\/1536867X1301300407","volume":"13","author":"C Li","year":"2013","unstructured":"Li C. Little\u2019s test of missing completely at random. Stata J. 2013;13(4):795\u2013809. https:\/\/doi.org\/10.1177\/1536867X1301300407.","journal-title":"Stata J"},{"key":"6263_CR43","unstructured":"Buuren S. Flexible imputation of missing data. 2nd ed: Chapman and Hall\/CRC; 2018."},{"issue":"1","key":"6263_CR44","doi-asserted-by":"publisher","first-page":"32","DOI":"10.55563\/clinexprheumatol\/gdps1r","volume":"39","author":"DE Marsman","year":"2021","unstructured":"Marsman DE, den Broeder N, Boers N, van den Hoogen FHJ, den Broeder AA, van der Maas A. Polymyalgia rheumatica patients with and without elevated baseline acute phase reactants: distinct subgroups of polymyalgia rheumatica? Clin Exp Rheumatol. 2021;39(1):32\u20137.","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"6263_CR45","doi-asserted-by":"publisher","first-page":"160018","DOI":"10.1038\/sdata.2016.18","volume":"3","author":"MD Wilkinson","year":"2016","unstructured":"Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, et al. The FAIR Guiding Principles for scientific data management and stewardship. Sci Data. 2016;3(1):160018. https:\/\/doi.org\/10.1038\/sdata.2016.18.","journal-title":"Sci Data"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06263-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06263-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06263-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T15:06:09Z","timestamp":1650121569000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06263-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["6263"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06263-3","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,15]]},"assertion":[{"value":"28 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study follows the principles of the Declaration of Helsinki as put forward by the World Medical Association (most recent version dating 2008) and all relevant Dutch legislation, including the Medical Research Involving Human Subjects Act (WMO), the Medical Treatment Agreements Act (WGBO), and the Personal Data Protection Act (WBP). This study will be performed in accordance with the Good Clinical Practice and the Dutch guidelines on quality assurance for research involving human subjects (<i>Kwaliteitsborging mensgebonden onderzoek<\/i> 2.0) of the Netherlands Federation of University Medical Centers (NFU) dating March 2019. Informed consent will be obtained from all study participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"318"}}